Sign in Subscribe
United States. Securities and Exchange Commission

Neurocrine Biosciences Settles Patent Litigation with Lupin Limited

Strategic Insights

— 1 min read

Neurocrine Biosciences, Inc., a Delaware-based biopharmaceutical company, has resolved patent litigation with Lupin Limited, a global pharmaceutical company, regarding its medication Ingrenza (KV vs. INGREZZA), used to treat tardive dyskinesia and chorea associated with Huntington's disease. The settlement, announced on November 9, 2023, allows Lupin to sell generic versions of Ingrenza in the United States starting from March 1, 2038, or earlier under certain circumstances. This settlement comes after a series of patent litigation cases, with similar agreements already in place with other companies, including Sandoz and Teva.

Key Takeaways:

  • Neurocrine Biosciences has settled patent litigation with Lupin Limited regarding its medication Ingrenza.
  • The settlement grants Lupin the right to sell generic versions of Ingrenza in the United States starting from March 1, 2038, or earlier under certain circumstances.
  • Similar patent litigation with other companies, including Sandoz and Teva, remains pending, with trial dates set for 2024.
  • The company has entered into agreements with Sandoz, Crystal, and Teva, granting them the right to sell generic versions of Ingrenza in the United States starting from March 1, 2038, or earlier under certain circumstances.
  • As required by law, the company and Lupin will submit the agreement to the United States Federal Trade Commission and the United States Department of Justice.
  • The settlement is a significant development in the patent litigation landscape surrounding Neurocrine Biosciences' Ingrenza medication.

Statistics:

  • 2038: The year by which Lupin is granted the right to sell generic versions of Ingrenza in the United States, starting from March 1.
  • 1 March 2038: The date by which Ingrenza's patent is expected to expire, allowing Lupin to sell generic versions.
  • $0.001: The par value of Neurocrine Biosciences' Common Stock listed on the Nasdaq Global Select Market.
  • 2024: The year in which trial dates are set for similar patent litigation cases with Sandoz, Crystal, and Teva.

Sources:

  • Neurocrine Biosciences, Inc. FORM 8-K (Current Report) filing with the U.S. Securities and Exchange Commission, dated November 9, 2023.

Read more